$148.05
-0.93-0.62%
Last update: 9:27 AM
15 minutes delayed
Sarepta Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Sarepta Therapeutics using advanced sorting and filters.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
SRPT | Sarepta Therapeutics | -$0.85 | $0.02 | — | — | $261.24M | $396.26M | — | — | 07/31/2024 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.99 | -$0.07 | $0.73 | 1142.86% | $253.50M | $373.28M | $413.46M | 10.77% | 05/01/2024 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.53 | $0.01 | $0.82 | 8100.00% | $258.43M | $385.81M | $396.78M | 2.84% | 02/28/2024 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.80 | -$1.32 | $0.37 | 128.03% | $230.27M | $288.50M | $331.82M | 15.01% | 11/01/2023 | Get Alert |
SRPT | Sarepta Therapeutics | -$1.18 | -$1.89 | -$0.85 | 55.03% | $233.49M | $264.45M | $261.24M | -1.21% | 08/02/2023 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.56 | -$1.38 | -$0.97 | 29.71% | $210.83M | $241.96M | $253.50M | 4.77% | 05/02/2023 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.77 | -$1.35 | -$0.53 | 60.74% | $201.46M | $248.34M | $258.43M | 4.06% | 02/28/2023 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.19 | -$1.43 | -$0.80 | 44.06% | $189.41M | $234.52M | $230.27M | -1.81% | 11/02/2022 | Get Alert |
SRPT | Sarepta Therapeutics | -$1.52 | -$1.18 | -$1.18 | 0.00% | $164.09M | $220.81M | $233.49M | 5.74% | 08/02/2022 | Get Alert |
SRPT | Sarepta Therapeutics | -$1.54 | -$1.27 | -$0.56 | 55.91% | $146.93M | $206.44M | $210.83M | 2.13% | 05/04/2022 | Get Alert |
SRPT | Sarepta Therapeutics | -$1.84 | -$1.13 | -$0.77 | 31.86% | $145.14M | $198.61M | $201.46M | 1.44% | 03/01/2022 | Get Alert |
SRPT | Sarepta Therapeutics | -$1.42 | -$1.89 | -$0.19 | 89.95% | $143.92M | $173.42M | $189.41M | 9.22% | 11/03/2021 | Get Alert |
SRPT | Sarepta Therapeutics | -$1.51 | -$1.29 | -$1.52 | -17.83% | $137.36M | $162.64M | $164.09M | 0.89% | 08/04/2021 | Get Alert |
SRPT | Sarepta Therapeutics | -$1.04 | -$1.78 | -$1.54 | 13.48% | $113.67M | $143.33M | $146.93M | 2.51% | 05/05/2021 | Get Alert |
SRPT | Sarepta Therapeutics | -$1.57 | -$1.77 | -$1.84 | -3.95% | $100.11M | $146.29M | $145.14M | -0.79% | 03/01/2021 | Get Alert |
SRPT | Sarepta Therapeutics | -$1.14 | -$1.71 | -$1.42 | 16.96% | $99.04M | $137.43M | $143.92M | 4.73% | 11/05/2020 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.83 | -$1.72 | -$1.51 | 12.21% | $94.67M | $118.78M | $137.36M | 15.64% | 08/05/2020 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.75 | -$1.78 | -$1.04 | 41.57% | $87.01M | $119.15M | $113.67M | -4.60% | 05/06/2020 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.85 | -$1.86 | -$1.57 | 15.59% | $84.42M | $98.85M | $100.11M | 1.28% | 02/26/2020 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.56 | -$1.36 | -$1.14 | 16.18% | $78.49M | $96.99M | $99.04M | 2.11% | 11/07/2019 | Get Alert |
SRPT | Sarepta Therapeutics | -$0.43 | -$1.37 | -$0.83 | 39.42% | $73.53M | $90.94M | $94.67M | 4.10% | 08/07/2019 | Get Alert |
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-01 | $0.73 | $-0.07 | 1142.9 % |
Dec 2023 | 2024-02-28 | $0.82 | $0.01 | 8100.0 % |
Sep 2023 | 2023-11-01 | $0.37 | $-1.32 | 128.0 % |
Jun 2023 | 2023-08-02 | $-0.85 | $-1.89 | 55.0 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-01 | $413.46M | $373.28M | 10.8 % |
Dec 2023 | 2024-02-28 | $396.78M | $385.81M | 2.84 % |
Sep 2023 | 2023-11-01 | $331.82M | $288.50M | 15.0 % |
Jun 2023 | 2023-08-02 | $261.24M | $264.45M | -1.21 % |
Sarepta Therapeutics (SRPT) is scheduled to report earnings on July 31, 2024. The last reported earnings were for reported on May 1, 2024 for Q1.
The Actual EPS was $0.73, which beat the estimate of $-0.07.
The Actual Revenue was $413.5M, which beat the estimate of $373.3M.
Browse earnings estimates, EPS, and revenue on all stocks.